Clinical Trial Update: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant Cretostimogene Grenadanorepvec for intermediate-risk non-muscle invasive bladder cancer after TURBT is currently ACTIVE_NOT_RE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Cretostimogene Grenadanorepvec

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING